The cooling-heat medicine Compound Kushen injection significantly improved the sensitivity of gefitinib on less sensitive NSCLC cells in a combinatorial fashion through the PI3K/AKT/mTOR signaling pathway [27]. The gene discussed is PIK3CA; the disease is non-small cell lung carcinoma.